|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM03032369X |
| 003 |
DE-627 |
| 005 |
20250126115008.0 |
| 007 |
tu |
| 008 |
231221s1988 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0101.xml
|
| 035 |
|
|
|a (DE-627)NLM03032369X
|
| 035 |
|
|
|a (NLM)3051044
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Owen, S
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A controlled trial of an oral bronchodilator preparation ('Franol') in asthma
|
| 264 |
|
1 |
|c 1988
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.11.1988
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a In view of the lack of published data on the oral bronchodilator preparation 'Franol' (120 mg theophylline, 11 mg ephedrine hydrochloride and 8 mg phenobarbitone per tablet) a double-blind study was carried out to compare the effects on lung function of a single dose of 2 'Franol' tablets, 1 'Franol' plus 1 placebo tablet, or 2 placebo tablets over a period of 8 hours in 30 asthmatic patients with reversible airways resistance (mean FEV1 1.31 l increasing to 1.71 l after 200 micrograms salbutamol inhalation). 'Franol' produced dose-dependent bronchodilation. Two tablets caused significant bronchodilation from 90 minutes to 8 hours (peak change from baseline at 2.5 hours: FEV1 20.8%, PEFR 22.3%). One tablet of 'Franol' produced significant bronchodilation only between 60 minutes and 3 hours (change from baseline at 2.5 hours: FEV1 7.5%, PEFR 7.9%). There was no change in lung function with placebo (change from baseline at 2.5 hours: FEV1 5.4%, PEFR 5.9%). Median serum theophylline levels at 2.5 hours were 6.38 micrograms/ml for 2 tablets and 3.18 micrograms/ml for 1 tablet. Median peak phenobarbitone levels were 0.5 micrograms/ml. There were no clinically relevant changes in pulse rate and blood pressure during the study and no adverse events were reported
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Controlled Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Bronchodilator Agents
|2 NLM
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Ethylenediamines
|2 NLM
|
| 650 |
|
7 |
|a franol
|2 NLM
|
| 650 |
|
7 |
|a 8058-86-4
|2 NLM
|
| 650 |
|
7 |
|a Theophylline
|2 NLM
|
| 650 |
|
7 |
|a C137DTR5RG
|2 NLM
|
| 650 |
|
7 |
|a Ephedrine
|2 NLM
|
| 650 |
|
7 |
|a GN83C131XS
|2 NLM
|
| 650 |
|
7 |
|a Phenobarbital
|2 NLM
|
| 650 |
|
7 |
|a YQE403BP4D
|2 NLM
|
| 700 |
1 |
|
|a Stone, P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Campbell, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Webster, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Woodstock, A A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Pharmatherapeutica
|d 1985
|g 5(1988), 4 vom: 11., Seite 240-5
|w (DE-627)NLM023961570
|x 0308-051X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:5
|g year:1988
|g number:4
|g day:11
|g pages:240-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 5
|j 1988
|e 4
|b 11
|h 240-5
|